Seoul National University Bundang Hospital
Seongnam, South Korea
143 recruiting
Showing 1–20 of 249 trials
Recruiting
Phase 1
A Study to Evaluate Safety, Pharmacokinetics, and Activity of GDC-7035 as a Single Agent and in Combination in Patients With Advanced Solid Tumors
Solid Tumor
Genentech, Inc.410 enrolled38 locationsNCT06619587
Recruiting
Phase 3
Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma
Endometrial CarcinomaEndometrial Clear Cell AdenocarcinomaEndometrial Dedifferentiated Carcinoma+5 more
National Cancer Institute (NCI)360 enrolled408 locationsNCT05256225
Recruiting
Phase 3
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
Breast Cancer
Hoffmann-La Roche450 enrolled226 locationsNCT06790693
Recruiting
Phase 3
A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
CRC (Colorectal Cancer)
Incyte Corporation700 enrolled273 locationsNCT07284849
Recruiting
Phase 3
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
Breast Cancer
Pfizer400 enrolled384 locationsNCT07062965
Recruiting
Phase 3
A Study of Mezagitamab in Adults With Primary IgA Nephropathy Kidney Condition
Kidney Disease
Takeda347 enrolled153 locationsNCT06963827
Recruiting
Phase 3
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
Triple-Negative Breast Cancer
Gilead Sciences1,514 enrolled339 locationsNCT05633654
Recruiting
Phase 3
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
Non-small Cell Lung Cancer (NSCLC)
Bristol-Myers Squibb850 enrolled254 locationsNCT07361497
Recruiting
Phase 3
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
Relapsed or Refractory Multiple Myeloma
Celgene810 enrolled266 locationsNCT05519085
Recruiting
Phase 1Phase 2
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
Metastatic Breast CancerColorectal, CancerEsophageal Adenocarcinoma+2 more
Boehringer Ingelheim768 enrolled108 locationsNCT06324357
Recruiting
Phase 3
Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis
Primary Biliary Cholangitis
Gilead Sciences318 enrolled196 locationsNCT06051617
Recruiting
Phase 3
A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
Immune Thrombocytopenic Purpura (ITP)
Takeda150 enrolled108 locationsNCT06948318
Recruiting
Phase 3
A Study to Test Whether Nerandomilast Helps People With Lungfibrosis Related to Rheumatic Diseases
Interstitial Lung DiseasesSystemic Autoimmune Rheumatic Diseases Associated Interstitial Lung Diseases
Boehringer Ingelheim400 enrolled158 locationsNCT06806592
Recruiting
Phase 3
A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure
Heart Failure
Boehringer Ingelheim6,000 enrolled653 locationsNCT06424288
Recruiting
Phase 3
Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML
Leukemia
Daiichi Sankyo700 enrolled288 locationsNCT06578247
Recruiting
Phase 3
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
Cardiovascular DiseasesHypertensionDiabetes Mellitus, Type 2
Boehringer Ingelheim11,800 enrolled1152 locationsNCT07064473
Recruiting
Phase 1Phase 2
LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve
Non-muscle Invasive Bladder Cancer With Carcinoma in SituSuperficial Bladder Cancer
enGene, Inc.350 enrolled101 locationsNCT04752722
Recruiting
Phase 3
A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart
Heart Failure
Boehringer Ingelheim4,200 enrolled638 locationsNCT06935370
Recruiting
Phase 3
A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast
Progressive Pulmonary FibrosisIdiopathic Pulmonary Fibrosis
Boehringer Ingelheim1,700 enrolled371 locationsNCT06238622
Recruiting
Phase 1Phase 2
Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)
Pancreatic CancerGastric CancerNon-small Cell Lung Cancer (NSCLC)+2 more
EMD Serono Research & Development Institute, Inc.250 enrolled81 locationsNCT06710132